| Hazard Information | Back Directory | [Uses]
Cifurtilimab (SEA-CD40) is an agonistic nonfucosylated, human IgG1 monoclonal antibody directed against CD40. Cifurtilimab shows antitumor activities[1][2]. | [in vivo]
In preclinical mouse models, Cifurtilimab combined with chemotherapeutic agents to drive robust anti-tumor activity[2]. | [References]
[1] Neff-LaFord H, et al. SEA-CD40 is a non-fucosylated anti-CD40 antibody with potent pharmacodynamic activity in preclinical models and patients with advanced solid tumors. Cancer Research, 2020, 80(16_Supplement): 5535-5535.
[2] Zeng W, et al. 438 Synergy between SEA-CD40 and chemotherapeutics drives curative antitumor activity in preclinical models. 2020. |
|
| Company Name: |
TargetMol
|
| Telephone: |
400-821-0310 15002144251 |
| Website: |
www.targetmol.cn/ |
|